Carole Ho - 12 Aug 2025 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Chief Medical Officer
Issuer ticker: DNLI
Reported as of: 12 Aug 2025
Net transaction value: -$51,684
SEC form: 4
Accepted by SEC: 14 Aug 2025, 20:33:05 UTC
Prior SEC filing: 07 Aug 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Carole Ho filed Form 4 for Denali Therapeutics Inc. (DNLI) on 14 Aug 2025.

Key facts

This page summarizes Carole Ho's Form 4 filing for Denali Therapeutics Inc. (DNLI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 20:33.

Change

Previous filing in this sequence was filed on 07 Aug 2025.
Current net transaction value: -$51,684.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724605 Primary reporting owner

Ho Carole

Relationship: Chief Medical Officer
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Sale

Transaction value: $39,884
Shares: -2,937
Change %: -1.3%
Price: $13.58
Shares after: 217,391
Date: 12 Aug 2025
Ownership: Direct
Footnotes: F1, F2, F3

DNLI transaction

Common Stock

Sale

Transaction value: $11,800
Shares: -806
Change %: -0.37%
Price: $14.64
Shares after: 216,585
Date: 13 Aug 2025
Ownership: Direct
Footnotes: F3, F4

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 183,219
Date: 12 Aug 2025
Ownership: See footnote
Footnotes: F5

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,000
Date: 12 Aug 2025
Ownership: See footnote
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

Footnote F2

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

Includes 128,405 Unvested RSUs.

Footnote F4

The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.

Footnote F5

The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

Footnote F6

The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.